Pyrantel Pamoate Chewable Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 11 mg
Reference Brands: Pin-X(US),Combantrin(EU)
Category:
Anthelmintic
Pyrantel pamoate is an anthelmintic that depolarizes neuromuscular junctions in parasitic worms, causing paralysis and expulsion from the intestines. It effectively treats roundworms, hookworms, and pinworms. Benefits include rapid infection clearance, symptom relief, reduced transmission, and supporting gastrointestinal health in parasitic infestations worldwide.
Pyrantel Pamoate chewable tablets is available in Tablets
and strengths such as 11 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pyrantel Pamoate chewable tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pyrantel Pamoate chewable tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pyrantel pamoate tablets, marketed as Pin-X in the US and as generic or local brands in the EU, are approved for treating intestinal parasitic infections. Regulatory approval requires the submission of dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews clinical trial and quality data for timely approval, whereas the EU’s EMA ensures compliance with regional safety standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper compliance supports swift approval, safe use, and global availability, enabling effective antiparasitic therapy worldwide for children and adults.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing